Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Ultraviolet Therapy × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3 Lymphoid 3 Genitourinary 2 Dermatologic 2 Breast 2 Thoracic 1 Plasma cell 1 Myeloid 1 Classical hematology 1

Conditions

Pleural Malignancy 1

Interventions

Carboplatin 958 Cisplatin 759 Pemetrexed 700 pembrolizumab 510 Paclitaxel 493 Docetaxel 456 Gemcitabine 354 Radiotherapy 329 Erlotinib Hydrochloride 315 Bevacizumab 274 Nivolumab 264 Etoposide 247 durvalumab 221 Drug Therapy 194 osimertinib 184 atezolizumab 175 Radiosurgery 160 Gefitinib 151 Vinorelbine 128 Magnetic Resonance Spectroscopy 105 130-nm albumin-bound paclitaxel 104 Ipilimumab 97 Cetuximab 97 Topotecan 89 Cyclophosphamide 88 tislelizumab 82 Irinotecan 81 anlotinib 79 Taxes 78 Albumin-Bound Paclitaxel 77

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01673074 2020-04-08

HPPH and PDT for Pleural Malignancy

Abramson Cancer Center at Penn Medicine

Phase 1 Completed

Pleural Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡